Immunomedics (Immunomedics) Cash-to-Debt : 3.26 (As of Jun. 2020)

View and export this data going back to 1990. Start your Free Trial

What is Immunomedics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immunomedics's cash to debt ratio for the quarter that ended in Jun. 2020 was 3.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Immunomedics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2020.

The historical rank and industry rank for Immunomedics's Cash-to-Debt or its related term are showing as below:

IMMU' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: 309.68 Max: No Debt
Current: 3.26

During the past 13 years, Immunomedics's highest Cash to Debt Ratio was No Debt. The lowest was 0.33. And the median was 309.68.

IMMU's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs IMMU: 3.26

Immunomedics Cash-to-Debt Historical Data

The historical data trend for Immunomedics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Immunomedics Cash-to-Debt Chart

Immunomedics Annual Data

Trend

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

1.03

0.52

1.58

2.88

2.28

Immunomedics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Cash-to-Debt	Get a 7-Day Free Trial															1.74	1.43	2.28	1.90	3.26

Competitive Comparison of Immunomedics's Cash-to-Debt

For the Biotechnology subindustry, Immunomedics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunomedics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunomedics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Immunomedics's Cash-to-Debt falls into.

Immunomedics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Immunomedics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	613.178	/	(10.898	+	257.769)
	=	2.28

Immunomedics's Cash to Debt Ratio for the quarter that ended in Jun. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	975.518	/	(21.399	+	277.432)
	=	3.26

Immunomedics (NAS:IMMU) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Immunomedics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Immunomedics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunomedics (Immunomedics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 The American Road, Morris Plains, NJ, USA, 07950

Website

http://www.immunomedics.com

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Executives

Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt	director
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc	director, 10 percent owner, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	director, 10 percent owner, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian	director, officer: President and CEO	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews	officer: Chief Human Resources Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg	officer: General Counsel	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik	officer: Chief Business Officer & CFO	300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney	officer: Chief Commerical Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri	officer: Chief Medical Officer